Core Insights - The market regulatory authority has reported significant achievements in the pilot program for operator concentration review, with 1,288 cases reviewed and a total transaction value exceeding 3 trillion yuan over three years [1][2][3] Group 1: Pilot Program Achievements - The pilot program, initiated from August 1, 2022, to July 31, 2025, has successfully enhanced the efficiency of corporate mergers and acquisitions, significantly stimulating the vitality of business entities [1][2] - The program has resulted in an average processing time of 16.9 days for acceptance and 17.4 days for case resolution, indicating a high level of efficiency comparable to the central authority [2][3] Group 2: Regulatory Framework and Future Plans - The market regulatory authority plans to formalize the pilot program into a permanent system starting August 1, 2025, to ensure stability and continuity in the review process [3][4] - New regulatory guidelines and manuals are being developed to standardize review criteria and enhance transparency, which will support the establishment of a unified national market [4] Group 3: Enforcement Actions - The authority has taken strict enforcement actions against anti-competitive practices, including prohibiting one merger and approving three with conditions to mitigate competitive concerns [4][5] - The recent prohibition of a merger involving Wuhan Yutong Medical Co., Ltd. marks a significant enforcement action, being the fourth such prohibition since the antitrust law was enacted in 2008 [5]

新华社北京8月15日电 题：创新监管制度 激发企业活力——市场监管总局持续提升经营者集中反垄 断审查效能 "目前，我们还在制定《非横向经营者集中审查指引》《经营者集中申报规范》《省级市场监管部 门经营者集中审查工作手册》等规则，进一步强化审查工作统一性和规范化，提高工作透明度和可预期 性，为建设全国统一大市场提供坚实制度保障。"徐乐夫说。 近期市场监管总局禁止了1起经营者集中案件，附条件批准了3起经营者集中案件，引发社会关注。 经营者集中审查是我国反垄断执法机构对企业间通过合并、股权控制、合同控制等方式形成控制关 系的事前审查制度，旨在预防市场垄断行为、维护公平竞争秩序。 为加强相关事前监管，市场监管总局自2022年8月1日至2025年7月31日选取北京等5个省级市场监管 部门作为试点，审查范围辐射全国重点经济区域，更好地服务国家经济发展战略全局。 "经评估，3年试点工作取得了显著成效，达到了委托审查制度实施的预期目的。"市场监管总局反 垄断执法二司司长徐乐夫在发布会上介绍，试点3年来，市场监管总局共委托地方审查案件1288件，占 同期全部案件数量的54%，案件交易总金额超过3万亿元，大幅提高企业投资并购效率 ...

本案是2008年《中华人民共和国反垄断法》施行以来第四起禁止的经营者集中案件，是第一起对未达申 报标准的经营者集中予以禁止的案件，也是首次要求相关方对已实施的集中采取措施恢复到集中前状 态。 作为药品垄断的重灾区，原料药领域的反垄断治理再添一例典型案件——两家药企六年前的股权交易被 要求限时恢复原状。 近日，因常年占据一款医保覆盖并纳入地方集采的血管扩张类药物上游80％原料药销售市场，却又通过 股权收购取得对下游制剂企业的控制权，导致药物平均出厂价一度涨超60％，一家湖北药企的收购行为 被市场监管总局判具有排除、限制竞争效果，该局决定禁止此项经营者集中行为并要求该药企6年前的 收购限时解除。 "本案是2008年《中华人民共和国反垄断法》施行以来第四起禁止的经营者集中案件，是第一起对未达 申报标准的经营者集中予以禁止的案件，也是首次要求相关方对已实施的集中采取措施恢复到集中前状 态。"市场监管总局官方微信公号刊文指出。 市场监管总局披露的数据显示，2019年至2022年，从我国盐酸罂粟碱注射剂企业原料药来源看，武汉用 通占比分别为90%~95%、80%~85%、80%~85%、80%~85%，具有较强市场控制力 ...

本项集中涉及民生药品盐酸罂粟碱注射剂。盐酸罂粟碱注射剂是一种血管扩张药，主要用于治疗脑、心 及外周血管痉挛所致的缺血，肾、胆或胃肠道等内脏痉挛，且在手指显微手术中具有独特疗效，其他血 管扩张药无法对其有效替代。 南都讯 记者黄莉玲 7月23日市场监管总局在官网公布，禁止武汉用通医药有限公司（以下简称武汉用 通）收购山东北大高科华泰制药有限公司（以下简称山东华泰制药）股权案件。 据悉，本案是2008年《中华人民共和国反垄断法》施行以来第四起禁止的经营者集中案件，是第一起对 未达申报标准的经营者集中予以禁止的案件，也是首次要求相关方对已实施的集中采取措施恢复到集中 前状态。 不仅如此，通报还谈及集中后实体具有排除、限制中国境内盐酸罂粟碱注射剂市场竞争的动机，且产生 了排除、限制竞争效果。具体表现为集中后山东华泰制药在下游市场的份额明显提升；盐酸罂粟碱注射 剂价格显著上涨，严重损害下游消费者权益。 官方披露数据显示，2016年9月，武汉用通成为青海制药原料药独家销售商后，原料药价格大幅上涨， 盐酸罂粟碱注射剂价格也随之上涨，2018年平均出厂价格较2017年上涨超过400%。集中完成后，2019 年盐酸罂粟碱注射剂 ...

Core Viewpoint - The State Administration for Market Regulation has prohibited Wuhan Yitong Pharmaceutical Co., Ltd. from acquiring shares of Shandong Huatai Pharmaceutical Co., Ltd. due to antitrust concerns, emphasizing the need to maintain competition in the market for hydrochloride poppy alkaloid injection [1][2] Group 1 - The acquisition was deemed to have an exclusionary and restrictive effect on competition in the hydrochloride poppy alkaloid injection market in China [1] - Wuhan Yitong is required to transfer its indirect holdings in Shandong Huatai Pharmaceutical to an unrelated third party by January 22, 2026, and must not participate in the management of Shandong Huatai during this period [1] - If the share transfer is not completed by the deadline, Wuhan Yitong must apply to the market regulator for an extension and provide reasons for the delay [1] Group 2 - By September 30, 2025, Wuhan Yitong must terminate its agency agreement for hydrochloride poppy alkaloid raw materials with Qinghai Pharmaceutical and cannot execute related agreements until this is resolved [2] - The ultimate controller of Wuhan Yitong has committed not to engage in any future operator concentration in the fields of hydrochloride poppy alkaloid raw materials and injections [2] - The market regulator retains the authority to supervise and inspect Wuhan Yitong and its ultimate controller's compliance with these obligations [2]